Humacyte Inc (NASDAQ: HUMA) is 100.35% higher on its value in year-to-date trading and has touched a low of $1.96 and a high of $9.97 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The HUMA stock was last observed hovering at around $5.53 in the last trading session, with the day’s gains setting it 0.16%.
Currently trading at $5.69, the stock is -15.27% and -16.97% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.19 million and changing 2.80% at the moment leaves the stock 21.59% off its SMA200. HUMA registered 40.84% gain for a year compared to 6-month gain of 63.51%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -27.70% loss in the last 1 month and extending the period to 3 months gives it a -14.69%, and is -14.56% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.08% over the week and 8.71% over the month.
Humacyte Inc (HUMA) has around 183 employees, a market worth around $679.10M and $0.00M in sales. Distance from 52-week low is 190.31% and -42.93% from its 52-week high.
The EPS is expected to shrink by -12.31% this year
165.0 institutions hold shares in Humacyte Inc (HUMA), with institutional investors hold 38.29% of the company’s shares. The shares outstanding are 103.67M, and float is at 92.74M with Short Float at 12.31%. Institutions hold 26.57% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 7.14 million shares valued at $34.27 million. The investor’s holdings represent 6.5961 of the HUMA Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 4.73 million shares valued at $22.7 million to account for 4.3693 of the shares outstanding. The other top investors are STATE STREET CORP which holds 2.87 million shares representing 2.6501 and valued at over $13.77 million, while GEODE CAPITAL MANAGEMENT, LLC holds 1.7193 of the shares totaling 1.86 million with a market value of $8.93 million.
Humacyte Inc (HUMA) Insider Activity
The most recent transaction is an insider purchase by Niklason Laura E, the company’s President, CEO and Director. SEC filings show that Niklason Laura E bought 1,222 shares of the company’s common stock on Aug 29 ’24 at a price of $6.54 per share for a total of $7998.0. Following the purchase, the insider now owns 0.24 million shares.
Humacyte Inc disclosed in a document filed with the SEC on Aug 29 ’24 that Dougan Brady W (Director) bought a total of 1,222 shares of the company’s common stock. The trade occurred on Aug 29 ’24 and was made at $6.54 per share for $7998.0. Following the transaction, the insider now directly holds 0.24 million shares of the HUMA stock.
Still, SEC filings show that on Aug 29 ’24, Dougan Brady W (Director) disposed off 352,112 shares at an average price of $6.35 for $2.24 million. The insider now directly holds 3,677,262 shares of Humacyte Inc (HUMA).
